Cross-Sector entity

Scynexis

Company SCYX
8

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. Scynexis appears in 1 tracked Cross-Sector story from February 27, 2026.

1 verified story tracked

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · Scynexis

1 story
8 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Scynexis

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. Scynexis appears in 1 tracked Cross-Sector story from February 27, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Scynexis. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Scynexis 1

Biotech pharma Strongly negative 8

New York Issues Urgent Health Alert as Drug-Resistant Fungal Pathogen Spreads

New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.

2 sources